INVESTORS.

Regulus aims to develop novel oligonucleotide therapeutics that are designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases.

Home Page Ticker
NASDAQRGLS
Press Releases.
June 24, 2024
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Continued mechanistic dose response observed following completion of 3 mg/kg dose level based on urinary biomarker analyses Percent change from baseline in PC1 and PC2 demonstrated a dose response...

June 04, 2024
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today...

May 16, 2024
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today...

More press releases

Events.
Regulus Therapeutics Special Update Call
Monday, June 24, 2024
8:30am - 9:30am EDT
Canaccord Genuity Genetic Medicine for Generalists Webcast Series featuring Regulus Therapeutics (RGLS)| Hosted by Whitney Ijem
Wednesday, May 1, 2024
1:00pm - 2:00pm EDT
Regulus Special Update Call
Tuesday, March 12, 2024
8:30am - 9:30am EDT

More events

upcoming event.
No events to display

more events

email alerts.

Sign up for email alerts to receive the latest financial information from Regulus Therapeutics Inc.

Sign Up

IR contact.

Phone: 858-202-6300
Email: ir@regulusrx.com

Contact Us